FDA Adverse Event Reporting System analysis revealed significant disproportionate reporting of thyroid cancer with GLP-1 RAs, with reporting odds ratios ranging from 2.09 (tirzepatide) to 15.59 (liraglutide) [189]. This evidence concerns the gene GLP1R and thyroid gland carcinoma.